The FDA has granted a fast track designation to CLR 131 for use as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).1
A fast track designation has already been granted to CLR 131 for the treatment of patients with relapsed/refractory multiple myeloma, and the agent also received an orphan drug designation for the treatment of pediatric patients with osteosarcoma.
- Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma [press release]. Florham Park, NJ: Cellectar Biosciences; July 9, 2019. https://bit.ly/2Y1RfvD. Accessed July 9, 2019.
- Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients [press release]. Florham Park, NJ: Cellectar Biosciences; July 18, 2018. https://bit.ly/2Nt0LyW. Accessed July 9, 2019.
... to read the full story